FDA Inspection 1179266 — HCG Manavata Cancer Centre
The FDA completed an inspection of HCG Manavata Cancer Centre on August 6, 2022 in Nashik. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- August 6, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Nashik (India)
Additional Details
Clinical BA/BE